EDMONTON, Alberta, March 28, 2012 (GLOBE NEWSWIRE) -- Isotechnika Pharma Inc. (TSX:ISA) ("Isotechnika" or the "Company") announced today that, further to its press release of January 31, 2012, it has received notification that ILJIN Life Science Co., Ltd. ("ILJIN") has submitted a request for arbitration relating to Isotechnika's termination of their Development, Distribution and License Agreement (the "DDL").

"We are confident that our termination of the original DDL is valid, and are prepared for arbitration proceedings," commented Dr. Robert Foster, Isotechnika's CEO. "Our Company is equipped with the full rights to voclosporin for transplant and autoimmune indications in the United States, Europe and other regions outside of Canada, Israel, South Africa, China, Taiwan and Hong Kong. We plan on continuing to engage companies, including ILJIN, who have expressed interest in working with us to advance our lead program."

About Isotechnika Pharma Inc

Isotechnika Pharma Inc. is a biopharmaceutical company focused on the discovery and development of immunomodulating therapeutics designed to offer key safety advantages over currently available treatments. Its lead drug, voclosporin, is a calcineurin inhibitor, and is targeted at the estimated US$3.0 billion market for this class of immunosuppressants. Isotechnika Pharma Inc. trades on the Toronto Stock Exchange under the symbol "ISA". More information on Isotechnika Pharma can be found at www.isotechnika.com or www.sedar.com.

We seek Safe Harbour.